Tofacitinib
Indication
Rheumatoid arthritis (LSCMMG pathway)
MHRA Drug Safety Update, 6 October 2021
Major Adverse Cardiovascular Events MHRA Drug Safety Update
Red
Brand:
Xeljanz
Nice TA:
480
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
To be used according to the: 'Rheumatoid Arthritis LSCMMG Recommended High-Cost Drugs Pathway'
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: